Literature DB >> 31173759

Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Marco Pravetoni1, Sandra D Comer2.   

Abstract

Vaccines offer a promising therapeutic strategy to treat substance use disorders (SUD). Vaccines have shown extensive preclinical proof of selectivity, safety, and efficacy against opioids, nicotine, cocaine, methamphetamine, and designer drugs. Despite clinical evaluation of vaccines targeting nicotine and cocaine showing proof of concept for this approach, no vaccine for SUD has yet reached the market. This review first discusses how vaccines for treatment of opioid use disorders (OUD) and reduction of opioid-induced fatal overdoses fit within the current medication assisted treatment (MAT) portfolio, and then summarizes ongoing efforts toward translation of vaccines targeting heroin, oxycodone, fentanyl, and other opioids. This article is part of the Special Issue entitled 'New Vistas in Opioid Pharmacology'.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody; GMP; Opioid; Opioid epidemic; Translation; Vaccine

Mesh:

Substances:

Year:  2019        PMID: 31173759      PMCID: PMC6919211          DOI: 10.1016/j.neuropharm.2019.06.001

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  105 in total

1.  Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody.

Authors:  Kaspars Tars; Svetlana Kotelovica; Gerd Lipowsky; Monika Bauer; Roger R Beerli; Martin F Bachmann; Patrik Maurer
Journal:  J Mol Biol       Date:  2011-11-03       Impact factor: 5.469

2.  A protocol to switch high-dose, methadone-maintained subjects to buprenorphine.

Authors:  F R Levin; M W Fischman; I Connerney; R W Foltin
Journal:  Am J Addict       Date:  1997

Review 3.  Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors.

Authors:  Benito Anton; Alberto Salazar; Anabel Flores; Maura Matus; Rodrigo Marin; Jorge-Alberto Hernandez; Philippe Leff
Journal:  Hum Vaccin       Date:  2009-04-08

4.  Commentary - Building the evidence base for sustained public health response to the opioid epidemic in Canada.

Authors:  Theresa Tam
Journal:  Health Promot Chronic Dis Prev Can       Date:  2018-06       Impact factor: 3.240

5.  Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.

Authors:  Sandra D Comer; Eric D Collins; Herbert D Kleber; Elie S Nuwayser; James H Kerrigan; Marian W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-11-01       Impact factor: 4.530

6.  The interaction of 14C-morphine with sera from immunized rabbits and from patients addicted to heroin.

Authors:  J H Hill; B H Wainer; F W Fitch; R M Rothberg
Journal:  Clin Exp Immunol       Date:  1973-10       Impact factor: 4.330

7.  Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine.

Authors:  Gary R Matyas; Kenner C Rice; Kejun Cheng; Fuying Li; Joshua F G Antoline; Malliga R Iyer; Arthur E Jacobson; Alexander V Mayorov; Zoltan Beck; Oscar B Torres; Carl R Alving
Journal:  Vaccine       Date:  2014-01-28       Impact factor: 3.641

8.  Isolation of human monoclonal antibodies by mammalian cell display.

Authors:  Roger R Beerli; Monika Bauer; Regula B Buser; Myriam Gwerder; Simone Muntwiler; Patrik Maurer; Philippe Saudan; Martin F Bachmann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-23       Impact factor: 11.205

Review 9.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

10.  Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose.

Authors:  Megan Laudenbach; Federico Baruffaldi; Christine Robinson; Philipp Carter; Davis Seelig; Carly Baehr; Marco Pravetoni
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

View more
  19 in total

1.  Evaluation of a Dual Fentanyl/Heroin Vaccine on the Antinociceptive and Reinforcing Effects of a Fentanyl/Heroin Mixture in Male and Female Rats.

Authors:  E Andrew Townsend; Paul T Bremer; Kaycee E Faunce; S Stevens Negus; Alaina M Jaster; Hannah L Robinson; Kim D Janda; Matthew L Banks
Journal:  ACS Chem Neurosci       Date:  2020-04-22       Impact factor: 4.418

2.  Enhancement of a Heroin Vaccine through Hapten Deuteration.

Authors:  Tyson F Belz; Paul T Bremer; Bin Zhou; Beverly Ellis; Lisa M Eubanks; Kim D Janda
Journal:  J Am Chem Soc       Date:  2020-07-27       Impact factor: 15.419

3.  Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats.

Authors:  Bethany Crouse; Li Zhang; Christine Robinson; Yuguang Ban; Jennifer R Vigliaturo; Sabita Roy; Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2021-08-19       Impact factor: 4.526

4.  Evaluation of G protein bias and β-arrestin 2 signaling in opioid-induced respiratory depression.

Authors:  Jordan T Bateman; Erica S Levitt
Journal:  Am J Physiol Cell Physiol       Date:  2021-09-01       Impact factor: 5.282

5.  Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats.

Authors:  Carly Baehr; April Huseby Kelcher; Aaron Khaimraj; Dana E Reed; Sujata G Pandit; David AuCoin; Saadyah Averick; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2020-09-26       Impact factor: 4.030

Review 6.  Countermeasures for Preventing and Treating Opioid Overdose.

Authors:  Charles P France; Gerard P Ahern; Saadyah Averick; Alex Disney; Heather A Enright; Babak Esmaeli-Azad; Arianna Federico; Lisa R Gerak; Stephen M Husbands; Benedict Kolber; Edmond Y Lau; Victoria Lao; David R Maguire; Michael A Malfatti; Girardo Martinez; Brian P Mayer; Marco Pravetoni; Niaz Sahibzada; Phil Skolnick; Evan Y Snyder; Nestor Tomycz; Carlos A Valdez; Jim Zapf
Journal:  Clin Pharmacol Ther       Date:  2020-11-29       Impact factor: 6.875

7.  Confronting the opioid crisis with basic research in neuropharmacology.

Authors:  Michael H Baumann; Gavril W Pasternak; Sidney S Negus
Journal:  Neuropharmacology       Date:  2020-01-17       Impact factor: 5.250

Review 8.  Understanding and countering opioid-induced respiratory depression.

Authors:  Jordan T Bateman; Sandy E Saunders; Erica S Levitt
Journal:  Br J Pharmacol       Date:  2021-06-05       Impact factor: 8.739

9.  A Highly Efficacious Carfentanil Vaccine That Blunts Opioid-Induced Antinociception and Respiratory Depression.

Authors:  Lisa M Eubanks; Steven Blake; Yoshihiro Natori; Beverly Ellis; Paul T Bremer; Kim D Janda
Journal:  ACS Chem Biol       Date:  2021-02-03       Impact factor: 5.100

10.  Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders.

Authors:  April M Huseby Kelcher; Carly A Baehr; Fatima A Hamid; Geoffrey T Hart; Marco Pravetoni
Journal:  J Immunol       Date:  2021-07-19       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.